3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasms
805
Carcinoma, Non-Small-Cell Lung
768
Breast Neoplasms
731
Neoplasm Metastasis
341
Colorectal Neoplasms
340
Prostatic Neoplasms
324
Multiple Myeloma
309
Melanoma
305
Recurrence
237
Ovarian Neoplasms
237
Leukemia, Myeloid, Acute
236
Lymphoma, Non-Hodgkin
213
Lung Neoplasms
211
Carcinoma, Renal Cell
200
Lymphoma
190
Lymphoma, Follicular
164
Pancreatic Neoplasms
157
Leukemia, Lymphocytic, Chronic, B-Cell
149
Carcinoma, Hepatocellular
140
Stomach Neoplasms
137
Leukemia
133
Head and Neck Neoplasms
128
Lymphoma, Large B-Cell, Diffuse
126
Parkinson Disease 4, Autosomal Dominant Lewy Body
120
Squamous Cell Carcinoma of Head and Neck
110
Urinary Bladder Neoplasms
109
Carcinoma
101
Small Cell Lung Carcinoma
99
Triple Negative Breast Neoplasms
97
Glioblastoma
96
Interventions
dapagliflozin
1
Fulvestrant
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Has results
×
Hyperglycemia
×
Clear all
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts